Who makes Naïve patients - LNDL therapy?

Naïve patients - LNDL therapy is developed by National Liver Institute, Egypt.

What development phase is Naïve patients - LNDL therapy in?

Naïve patients - LNDL therapy is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Naïve patients - LNDL therapy

National Liver Institute, Egypt · FDA-approved active Small molecule Quality 0/100

Naïve patients - LNDL therapy, marketed by the National Liver Institute in Egypt, holds a niche position in the liver disease treatment landscape. The therapy's key composition patent is set to expire in 2028, providing a period of exclusivity that supports its market presence. However, the lack of detailed revenue and trial results data poses a significant risk in assessing its long-term commercial viability and competitive edge.

At a glance

Generic name	Naïve patients - LNDL therapy
Sponsor	National Liver Institute, Egypt
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Nitazoxanide and Lansoprazole Based Regimens for H. Pylori Management (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Naïve patients - LNDL therapy CI brief — competitive landscape report
Naïve patients - LNDL therapy updates RSS · CI watch RSS
National Liver Institute, Egypt portfolio CI